Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
-$5.5M |
 |
Gilead SciencesGILD |
-$4.04B |
 |
AmgenAMGN |
-$189M |
 |
Editas MedicineEDIT |
-$7M |
 |
Crispr TherapeuticsCRSP |
-$163M |
Are Lantheus Insiders Buying or Selling?
Lantheus (LNTH) has had no reported insider transactions in the past 90 days. The most recent was MARK WEHRLY, who sold 3,365,000 shares at $56.15 on August 20, 2025.
Insider trading patterns can signal confidence or concern from the people who know the company best. AltIndex tracks insider transactions as one of 25+ alternative data signals in the LNTH AI Score. For government officials trading this stock, see LNTH congressional trading.
Who’s Trading Lantheus Stock?
| Insider | Activity | Trades | Last Trade |
|---|---|---|---|
| FARALLON PARTNERS L L C/CA | Sold $191M | 2 | Aug 20, 2025 |
| MARK WEHRLY | Sold $191M | 2 | Aug 20, 2025 |
| Heino Mary Anne | Sold $8M | 12 | Jun 2, 2025 |
| Marshall Robert J. Jr. | Sold $5.1M | 5 | Jun 9, 2025 |
| Paul Blanchfield | Sold $1.1M | 4 | Aug 13, 2025 |
| Daniel Niedzwiecki | Sold $950,000 | 2 | Jun 13, 2025 |
Recent Lantheus Insider Transactions
| Insider | Transaction Date | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| MARK WEHRLY | Aug 20, 2025 | Sell | 3,365,000 | $56.15 | $189M |
| FARALLON PARTNERS L L C/CA | Aug 20, 2025 | Sell | 3,365,000 | $56.15 | $189M |
| MARK WEHRLY | Aug 19, 2025 | Sell | 41,000 | $55.34 | $2.3M |
| FARALLON PARTNERS L L C/CA | Aug 19, 2025 | Sell | 41,000 | $55.34 | $2.3M |
| Paul Blanchfield | Aug 13, 2025 | Sell | 3,060 | $53.57 | $160,000 |
| Daniel Niedzwiecki | Jun 13, 2025 | Sell | 6,000 | $78.74 | $470,000 |
| Marshall Robert J. Jr. | Jun 9, 2025 | Sell | 27,036 | $83.4 | $2.3M |
| Julie McHugh | Jun 9, 2025 | Sell | 5,192 | $81.62 | $420,000 |
| Marshall Robert J. Jr. | Jun 9, 2025 | Sell | 9,243 | $82.5 | $760,000 |
| Marshall Robert J. Jr. | Jun 9, 2025 | Sell | 3,494 | $81.27 | $280,000 |
| Paul Blanchfield | Jun 5, 2025 | Sell | 6,599 | $79.65 | $530,000 |
| Daniel Niedzwiecki | Jun 5, 2025 | Sell | 6,000 | $79.65 | $480,000 |
| Heino Mary Anne | Jun 2, 2025 | Sell | 22,926 | $77.09 | $1.8M |
| Heino Mary Anne | Jun 2, 2025 | Sell | 3,140 | $74.9 | $240,000 |
| Marshall Robert J. Jr. | Mar 17, 2025 | Sell | 10,000 | $100.52 | $1M |
| Heino Mary Anne | Mar 13, 2025 | Sell | 2 | $100.13 | $200 |
| Paul Blanchfield | Mar 5, 2025 | Sell | 2,084 | $98 | $200,000 |
| Heino Mary Anne | Mar 3, 2025 | Sell | 17,694 | $95.4 | $1.7M |
| Heino Mary Anne | Mar 3, 2025 | Sell | 15,017 | $94.09 | $1.4M |
| Heino Mary Anne | Mar 3, 2025 | Sell | 9,160 | $93.32 | $850,000 |
| Heino Mary Anne | Mar 3, 2025 | Sell | 6,265 | $92.29 | $580,000 |
| Heino Mary Anne | Mar 3, 2025 | Sell | 4,971 | $95.91 | $480,000 |
| James Thrall | Jan 15, 2025 | Sell | 1,000 | $94.76 | $95,000 |
| Marshall Robert J. Jr. | Nov 15, 2024 | Sell | 10,000 | $81.2 | $810,000 |
| Paul Blanchfield | Nov 14, 2024 | Sell | 2,000 | $79.65 | $160,000 |
| Heino Mary Anne | Nov 8, 2024 | Sell | 7,487 | $86.32 | $650,000 |
| Heino Mary Anne | Nov 8, 2024 | Sell | 2,900 | $88.78 | $260,000 |
| Heino Mary Anne | Nov 8, 2024 | Sell | 700 | $89.58 | $63,000 |
| Heino Mary Anne | Nov 8, 2024 | Sell | 400 | $86.93 | $35,000 |
Frequently Asked Questions: Lantheus Insider Trading
Lantheus insiders have not reported any transactions in the past 90 days.
The most recent sale was by MARK WEHRLY who sold 3,365,000 shares on August 20, 2025. View all transactions in the table on this page.
Insider buying is generally a stronger signal than insider selling, since insiders may sell for personal reasons (diversification, taxes) but typically buy only when they believe the stock is undervalued. AltIndex uses insider transaction patterns alongside 25+ other signals in the AI Score.
FARALLON PARTNERS L L C/CA has sold the most LNTH stock in the last 2 years, with a total value of $191M.
The total value of insider transactions for Lantheus in the last 2 years is negative, amounting to -$398M. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
